Dia Beta Labs Ltd is focused on addressing the challenges of metabolic diseases, particularly diabetes and obesity, through innovative therapeutic approaches. The company is developing a pipeline of novel therapeutic candidates that target insulin-producing pancreatic beta-cells. These candidates are designed to restore and enhance beta-cell health by preventing further decline, improving insulin release, and promoting cell proliferation. By leveraging re-engineered human peptide activators, Dia Beta Labs aims to exploit previously untapped receptors, thereby offering a more effective management strategy for metabolic diseases compared to existing treatments.

The therapeutic agents being developed by Dia Beta Labs are characterized by their enzyme resistance, which enhances their stability in plasma, and improved receptor selectivity, ensuring that they effectively target the intended biological pathways. Additionally, these peptides exhibit excellent solubility, facilitating easier formulation for therapeutic use. The company's commitment to transforming the lives of individuals suffering from metabolic diseases is underscored by its focus on creating sustainable weight loss solutions and preventing the progression of diabetes-related complications.

United Kingdom

Diabetes currently effects over 537 million adults worldwide, with obesity-driven Type 2 Diabetes accounting for over 90% of cases.

Dia Beta Labs build on over 30 years of high-impact research from our founding research group at Ulster University to realise the potential of next-generation therapeutics for metabolic disease.

It is our goal to impart significant and much-needed change in the management of the global diabetes/obesity crisis.

Dia Beta Labs Ltd

Company Details